SG Americas Securities LLC Cuts Position in Immatics N.V. $IMTX

SG Americas Securities LLC lowered its position in Immatics N.V. (NASDAQ:IMTX) by 52.3% in the first quarter, Holdings Channel reports. The fund owned 99,441 shares of the company’s stock after selling 109,015 shares during the period. SG Americas Securities LLC’s holdings in Immatics were worth $978,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its position in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares during the last quarter. Quarry LP purchased a new stake in shares of Immatics during the 4th quarter worth $84,000. Insigneo Advisory Services LLC purchased a new stake in shares of Immatics during the 3rd quarter worth $103,000. Engineers Gate Manager LP acquired a new position in shares of Immatics during the second quarter worth $124,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Immatics during the fourth quarter worth $129,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on IMTX. Jefferies Financial Group started coverage on Immatics in a research note on Monday, March 16th. They issued a “buy” rating and a $18.00 price target on the stock. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Immatics in a research note on Tuesday, May 19th. Weiss Ratings cut Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, TD Cowen initiated coverage on Immatics in a research report on Tuesday, April 28th. They set a “buy” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.

Immatics Price Performance

IMTX stock opened at $9.95 on Friday. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -5.00 and a beta of 1.32. The company has a fifty day moving average price of $10.47 and a 200 day moving average price of $10.17. Immatics N.V. has a 12 month low of $5.05 and a 12 month high of $12.41.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%.The business had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $9.79 million. As a group, analysts anticipate that Immatics N.V. will post -1.67 earnings per share for the current year.

Immatics Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.